Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis.
Journal
International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
14
03
2023
accepted:
26
06
2023
medline:
23
10
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
This review aims to compare the efficacies of fluorescence cystoscopy, narrow-band imaging (NBI), and white light cystoscopy in the treatment and diagnosis of bladder cancer. The authors searched PubMed, EMbase, Web of Science, and the Cochrane Library from January 1990 to April 2022. A total of 26 randomized controlled studies and 22 prospective single-arm studies were selected. Most patients had nonmuscle-invasive bladder cancer. The study protocol has been registered at PROSPERO. In the pairwise meta-analysis, 5-aminolevulinic acid (5-ALA) reduced the short-term and long-term recurrence rates of bladder cancer compared with white light cystoscopy (WLC); however, no statistical difference was observed in intermediate-term recurrence rates (RR=0.79, 95% CI: 0.57-1.09). Hexaminolevulinic acid and NBI reduced short-term, intermediate-term, and long-term recurrence rates. The sensitivity of 5-ALA, hexaminolevulinic acid, NBI, and WLC for bladder cancer were 0.89 (95% CI: 0.81-0.94), 0.96 (95% CI: 0.92-0.98), 0.96 (95% CI: 0.92-0.98), and 0.75 (95% CI: 0.70-0.79), respectively; however, only NBI had the same specificity as WLC (0.74 vs. 0.74). Compared with WLC, 5-ALA improved the detection rate of carcinoma in situ and Ta stage bladder cancer but had no advantage in T1 stage tumors (OR=2.39, 95% CI:0.79-7.19). Hexaminolevulinic acid and NBI improved the detection rates of all nonmuscular-invasive bladder cancers. In the network meta-analysis, there was no significant difference in either recurrence or detection rates between 5-ALA, hexaminolevulinic acid, and NBI. Fluorescence cystoscopy and NBI are advantageous for treating and diagnosing patients with nonmuscle-invasive bladder cancer.
Sections du résumé
BACKGROUND
BACKGROUND
This review aims to compare the efficacies of fluorescence cystoscopy, narrow-band imaging (NBI), and white light cystoscopy in the treatment and diagnosis of bladder cancer.
METHODS
METHODS
The authors searched PubMed, EMbase, Web of Science, and the Cochrane Library from January 1990 to April 2022. A total of 26 randomized controlled studies and 22 prospective single-arm studies were selected. Most patients had nonmuscle-invasive bladder cancer. The study protocol has been registered at PROSPERO.
RESULTS
RESULTS
In the pairwise meta-analysis, 5-aminolevulinic acid (5-ALA) reduced the short-term and long-term recurrence rates of bladder cancer compared with white light cystoscopy (WLC); however, no statistical difference was observed in intermediate-term recurrence rates (RR=0.79, 95% CI: 0.57-1.09). Hexaminolevulinic acid and NBI reduced short-term, intermediate-term, and long-term recurrence rates. The sensitivity of 5-ALA, hexaminolevulinic acid, NBI, and WLC for bladder cancer were 0.89 (95% CI: 0.81-0.94), 0.96 (95% CI: 0.92-0.98), 0.96 (95% CI: 0.92-0.98), and 0.75 (95% CI: 0.70-0.79), respectively; however, only NBI had the same specificity as WLC (0.74 vs. 0.74). Compared with WLC, 5-ALA improved the detection rate of carcinoma in situ and Ta stage bladder cancer but had no advantage in T1 stage tumors (OR=2.39, 95% CI:0.79-7.19). Hexaminolevulinic acid and NBI improved the detection rates of all nonmuscular-invasive bladder cancers. In the network meta-analysis, there was no significant difference in either recurrence or detection rates between 5-ALA, hexaminolevulinic acid, and NBI.
CONCLUSION
CONCLUSIONS
Fluorescence cystoscopy and NBI are advantageous for treating and diagnosing patients with nonmuscle-invasive bladder cancer.
Identifiants
pubmed: 37526087
doi: 10.1097/JS9.0000000000000592
pii: 01279778-202310000-00032
pmc: PMC10583940
doi:
Substances chimiques
Aminolevulinic Acid
88755TAZ87
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3169-3177Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Dobruch J, Oszczudlowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas) 2021;57:749.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–465.
Inoue K, Fukuhara H, Yamamoto S, et al. Current status of photodynamic technology for urothelial cancer. Cancer Sci 2022;113:392–398.
Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol 2012;188:361–368.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906.
Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
Riedl CR, Daniltchenko D, Koenig F, et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001;165:1121–1123.
Babjuk M, Soukup V, Petrík R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96:798–802.
Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002;168:475–478.
Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma. Urology 2002;60:1025–1028.
Stenzl A, Penkoff H, Dajc-Sommerer E, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2011;117:938–947.
Schumacher MC, Holmäng S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010;57:293–299.
Rolevich AI, Zhegalik AG, Mokhort AA, et al. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. World J Urol 2017;35:745–752.
Drăgoescu O, Tomescu P, Pănuş A, et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol 2011;52:123–127.
Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907–1913.
Geavlete B, Jecu M, Multescu R, et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer-re-TURBT recurrence rates in a prospective, randomized study. Urology 2010;76:664–669.
Karaolides T, Skolarikos A, Bourdoumis A, et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences. Urology 2012;80:354–359.
Drăgoescu PO, Tudorache Ş, Drocaş AI, et al. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. Rom J Morphol Embryol 2017;58:1279–1283.
O’Brien T, Ray E, Chatterton K, et al. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C versus conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096–1104.
Neuzillet Y, Methorst C, Schneider M, et al. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. Urol Oncol 2014;32:1135–1140.
Hermann GG, Mogensen K, Carlsson S, et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU International 2011;108(8 Pt 2):E297–E303.
Gkritsios P, Hatzimouratidis K, Kazantzidis S, et al. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial. Int Urol Nephrol 2014;46:927–933.
Drejer D, Moltke AL, Nielsen AM, et al. DaBlaCa-11: photodynamic diagnosis in flexible cystoscopy-a randomized study with focus on recurrence. Urology 2020;137:91–96.
Geavlete B, Multescu R, Georgescu D, et al. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. Urology 2012;79:846–851.
Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908–913.
Ma T, Wang W, Jiang Z, et al. Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. Zhonghua yi xue za zhi 2015;95:3032–3035.
Naito S, Algaba F, Babjuk M, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 2016;70:506–515.
Herr HW. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. Eur Urol 2015;67:605–608.
Buaban K, Attawettayanon W, Sirisreetreerux P, et al. Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. J Med Assoc Thai 2018;101:463–469.
Kim SB, Yoon SG, Tae J, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investig Clin Urol 2018;59:98–105.
Lee JY, Choi JH, Kim IK, et al. Mp22-16 recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. J Urol 2014;191:e240–e241.
Tschirdewahn S, Harke NN, Hirner L, et al. Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. World J Urol 2020;38:1509–1515.
Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: a prospective, randomized and multi-center study. Sci Rep 2015;5:10905.
Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a “second look” matters? Int Urol Nephrol 2012;44:451–457.
Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174:2129–2133.
Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007;69:675–679.
Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58–62.
Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999;13:117–121.
Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999;83:129–135.
Nakai Y, Inoue K, Tsuzuki T, et al. Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a multicenter phase III study. Int J Urol 2018;25:723–729.
Inoue K, Matsuyama H, Fujimoto K, et al. The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). Photodiagnosis Photodyn Ther 2016;13:91–96.
Schneeweiss S, Kriegmair M, Stepp H. Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol 1999;161:1116–1119.
Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. J Urol 2003;170:226–229.
Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68–73.
Palou J, Hernández C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. BJU Int 2015;116:37–43.
Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix(R)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc 2012;26:3634–3641.
Burgues JP, Conde G, Oliva J, et al. Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group. Actas Urol Esp 2011;35:439–445.
Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862–866.
Lee JS, Lee SY, Kim WJ, et al. Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer. Korean J Urol 2012;53:821–825.
Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009;56:914–919.
Ferré A, Cordonnier C, Demailly M, et al. Ciblage diagnostique par Hexvix® des tumeurs urothéliales de vessie: résultats après quatre ans d’évaluation prospective monocentrique. Progrès en Urologie 2013;23:195–202.
Daneshmand S, Bazargani ST, Bivalacqua TJ, et al. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry. Urol Oncol 2018;36:361.e1–361 e6.
Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int 2010;105:789–794.
Saint F, Elalouf V, Spie R, et al. Prospective monocentric evaluation of bladder tumor targeting by Hexvix (R) fluorescence: preliminary results. Prog Urol 2010;20:644–650.
Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 2010;24:1807–1811.
Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010;76:658–663.
Shadpour P, Emami M, Haghdani S. A comparison of the progression and recurrence risk index in non-muscle-invasive bladder tumors detected by narrow-band imaging versus white light cystoscopy, based on the EORTC scoring system. Nephrourol Mon 2016;8:e33240.
Hagiya Y, Endo Y, Yonemura Y, et al. Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro. Photodiagnosis Photodyn Ther 2012;9:204–214.
Inoue K, Karashima T, Kamada M, et al. Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology 2009;76:303–314.
Steinbach P, Kriegmair M, Baumgartner R, et al. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. Urology 1994;44:676–681.
Kutwin P, Konecki T, Cichocki M, et al. Photodynamic diagnosis and narrow-band imaging in the management of bladder cancer: a review. Photomed Laser Surg 2017;35:459–464.
Draga RO, Grimbergen MC, Kok ET, et al. Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnostics. Urology 2009;74:851–856.
Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. J Endourol 2009;23:977–981.